Concord Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Cash & Equivalents	84.6	151.42	34.99	6.67	51.44	24.08
Short-Term Investments	2,753	228.22	305.8	872.5	550	-
Trading Asset Securities	-	2,437	1,369	734.73	1,410	1,981
Cash & Short-Term Investments	2,837	2,817	1,710	1,614	2,011	2,005
Cash Growth	26.07%	64.71%	5.96%	-19.76%	0.31%	-
Accounts Receivable	3,444	3,496	2,738	2,322	1,775	1,835
Other Receivables	-	159.99	217.95	272.74	358.19	133.64
Receivables	3,444	3,656	2,956	2,594	2,133	1,969
Inventory	2,504	2,080	2,123	1,951	1,536	1,112
Prepaid Expenses	-	73.31	55.19	47.61	45.44	40.23
Other Current Assets	560.42	336.73	433.05	119.5	345.27	259.47
Total Current Assets	9,347	8,962	7,277	6,327	6,071	5,386
Property, Plant & Equipment	8,060	7,865	7,655	6,436	5,577	3,809
Long-Term Investments	4.55	20.7	79.25	2.56	3.66	8.15
Other Intangible Assets	7.84	3.2	1.98	35.77	64.18	0.93
Other Long-Term Assets	224.22	156.1	126.8	327.4	108.69	201.1
Total Assets	17,643	17,007	15,140	13,128	11,825	9,405
Accounts Payable	821.72	944.35	938	831.06	463.97	712.33
Accrued Expenses	-	168.21	146.19	131.45	102.38	75.61
Short-Term Debt	-	-	-	43.37	50.99	-
Current Portion of Long-Term Debt	-	62.3	250	250	250	125
Current Portion of Leases	18.17	16.21	1.47	15.96	13.01	10.91
Current Income Taxes Payable	19.16	54.94	89.99	-	-	17.82
Current Unearned Revenue	-	-	13.13	32.72	-	-
Other Current Liabilities	558.09	175.55	479.67	247.1	177.04	209.28
Total Current Liabilities	1,417	1,422	1,918	1,552	1,057	1,151
Long-Term Debt	-	-	62.36	312.49	562.5	355.28
Long-Term Leases	16.07	18.87	1.64	3.11	16.33	29.35
Long-Term Deferred Tax Liabilities	291.13	280.65	234.39	209.71	174.53	151.29
Other Long-Term Liabilities	15.33	19.56	22.97	18.74	20.98	15.94
Total Liabilities	1,740	1,741	2,240	2,096	1,832	1,703
Common Stock	104.62	104.62	104.62	95.11	95.11	95.11
Additional Paid-In Capital	-	819.71	819.71	829.22	829.22	829.22
Retained Earnings	-	14,342	11,976	10,108	9,069	6,778
Shareholders' Equity	15,904	15,266	12,900	11,032	9,994	7,702
Total Liabilities & Equity	17,643	17,007	15,140	13,128	11,825	9,405
Total Debt	34.24	97.38	315.46	624.93	892.83	520.54
Net Cash (Debt)	2,803	2,719	1,395	988.98	1,118	1,485
Net Cash Growth	38.70%	94.98%	41.02%	-11.58%	-24.66%	-
Net Cash Per Share	26.80	25.99	13.33	9.45	10.69	14.19
Filing Date Shares Outstanding	104.63	104.62	104.62	104.62	104.62	104.62
Total Common Shares Outstanding	104.63	104.62	104.62	104.62	104.62	104.62
Working Capital	7,929	7,541	5,359	4,775	5,014	4,235
Book Value Per Share	151.99	145.93	123.31	105.45	95.53	73.62
Tangible Book Value	15,896	15,263	12,898	10,996	9,930	7,701
Tangible Book Value Per Share	151.92	145.90	123.29	105.11	94.91	73.62
Land	-	547.11	547.11	547.11	546.99	543.41
Buildings	-	2,576	2,463	2,226	1,981	735.36
Machinery	-	4,979	4,788	4,285	3,773	1,776
Construction In Progress	-	2,115	1,727	741.55	179.46	1,414

Source: S&P Capital IQ. Standard template. Financial Sources.